BNP Paribas Financial Markets
GPCR icon

BNP Paribas Financial Markets’s Structure Therapeutics GPCR Stock Holding History

BNP Paribas Financial Markets’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$524K Buy
10,879
+2,133
+24% +$146K ﹤0.01% 3564
2025
Q4 		$608K Sell
8,746
-81,685
-90% -$3.34M ﹤0.01% 3466
2025
Q3 		$2.53M Buy
90,431
+24,595
+37% +$490K ﹤0.01% 2450
2025
Q2 		$1.37M Buy
65,836
+61,318
+1,357% +$1.35M ﹤0.01% 2724
2025
Q1 		$78.2K Sell
4,518
-6,700
-60% -$164K ﹤0.01% 4131
2024
Q4 		$304K Buy
+11,218
New +$398K ﹤0.01% 3618

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BNP Paribas Financial Markets's GPCR Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Structure Therapeutics (GPCR) stake by 24% in Q1 2026, buying an estimated $146K and bringing the position to 10,879 shares worth $524K. The position accounts for ﹤0.01% of the portfolio, ranked #3564.

BNP Paribas Financial Markets first reported a position in GPCR in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.53M in Q3 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • BNP Paribas Financial Markets held 10,879 shares of Structure Therapeutics worth $524K as of Q1 2026.
  • BNP Paribas Financial Markets bought 2,133 Structure Therapeutics shares in Q1 2026, an estimated $146K.
  • Structure Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3564 holding.
  • BNP Paribas Financial Markets first reported a position in Structure Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Structure Therapeutics position peaked at $2.53M in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.